1. Home
  2. CPRI vs PHVS Comparison

CPRI vs PHVS Comparison

Compare CPRI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

HOLD

Current Price

$16.67

Market Cap

2.4B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.26

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPRI
PHVS
Founded
1981
2015
Country
United Kingdom
Switzerland
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.4B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
CPRI
PHVS
Price
$16.67
$34.26
Analyst Decision
Buy
Buy
Analyst Count
13
11
Target Price
$26.62
$41.82
AVG Volume (30 Days)
2.5M
556.3K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
111.40
N/A
EPS
1.14
N/A
Revenue
$3,474,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.81
N/A
P/E Ratio
$15.32
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.72
$19.12
52 Week High
$28.27
$36.60

Technical Indicators

Market Signals
Indicator
CPRI
PHVS
Relative Strength Index (RSI) 33.66 55.66
Support Level N/A $24.73
Resistance Level $22.08 N/A
Average True Range (ATR) 0.82 1.59
MACD -0.26 -0.04
Stochastic Oscillator 0.18 36.21

Price Performance

Historical Comparison
CPRI
PHVS

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: